...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Any evidence of success in 2 subgroups

"Is there anything in the 2 subgroups, especially in the CKD group that could be a key indicator for the company that would tell them in their regular patient reports that the drug is working."

There are several measurements on blood samples that were previously documented to change in response to apabetalone including but not limited to apo-AI, HDL particle number, HDL-cholesterol, alkaline phosphatase, osteopontin, and several complement pathway, inflammation, acute phase response and coagulation proteins. Plus changes in eGFR and fasting glucose could be informative too. Although the data is blinded, Resverlogix and the clinical investigators may be able to observe changes in the total population consistent with the directionality of the previously reported apabetalone effects.

BearDownAZ

Share
New Message
Please login to post a reply